市場調查報告書
商品編碼
922048

全球患者腫瘤組織移植(PDX)模式市場:成長,趨勢,及預測

Patient Derived Xenograft Models Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球患者腫瘤組織移植(PDX)模式市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,類型·主要類型·終端用戶·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 個人化醫療的需求增加
    • 製藥產業研究開發活動的增加
    • 民間及民間部門對癌症研究的持續性支援
  • 市場阻礙因素
    • 個體化PDX模式的高成本
    • 使用動物模式的嚴格法規
  • 波特的五力分析

第5章 市場區隔

  • 各類型
    • 小鼠模型
    • 大鼠模型
  • 各腫瘤類型
    • 消化管腫瘤
    • 婦產科腫瘤
    • 呼吸系統腫瘤
    • 其他
  • 各終端用戶
    • 製藥·生物科技企業
    • 學術研究機關
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他

第6章 競爭情形

  • 企業簡介
    • Champions Oncology, Inc.
    • Charles River Laboratories, Inc.
    • Crown Bioscience, Inc.
    • EPO Berlin-Buch GmbH
    • Hera BioLabs
    • Horizon Discovery Group plc,
    • Oncodesign
    • Pharmatest Services Ltd
    • Urolead
    • Xentech

第7章 市場機會及今後趨勢

目錄
Product Code: 67577

Xenograft animal models are used to test the efficacy of medicines. They are primarily used for screenings and drug development for cancer, diabetes, infections, etc. Factors such as growing demand for personalized medicine, rising R&D activities in the pharmaceutical industry and continuous support for cancer research from the public as well as the private sector are driving the growth of the patient-derived xenograft models market. The mouse model of cancer has consistently been used to determine the in vivo activity of new anti-cancer therapeutics prior to clinical development and testing in humans. According to the World Cancer Research Fund, in 2018, there were around 18 million cancer cases worldwide. This leads to increased support from the public as well as the private sector associated with cancer research. Hence, the growing focus toward the development of better treatment options, along with the increasing burden of cancer is expected to drive the patient-derived xenograft models market.

However, the high cost of personalized PDX models is expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Respiratory Tumor Model Segment is Expected to Show Better Growth in the Forecast Period

Based on tumor type, the market is segmented into the gastrointestinal tumor model, gynecological tumor model, respiratory tumor model, and other tumor models. The respiratory tumor model segment is expected to grow at a faster pace during the forecast period. The key factor contributing to the growth of the segment include the growing research activities in the field of oncology and increasing focus of market players on generating lung cancer PDX models, along with the rising number of cancer cases. According to WHO, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Many companies are focusing on developing breakthrough products for the treatment of chronic disease in order to maintain their competitive advantage and penetrate new regional markets. Additionally, the increase in funding for companies involved in cancer research is expected to boost the studied market.

North America leads the Patient Derived Xenograft Models Market

North America leads the patient-derived xenograft models market owing to a rise in funding initiatives and awareness among patients regarding personalized medicine, followed by Europe. Patient-derived tumor xenografts are recognized as very relevant preclinical cancer models. As per American Cancer Society estimates, in 2018, there were 1,735,350 new cases of cancer diagnosed in the United States. Also, in 2018, the National Institute of Cancer expands the repository of cancer research models to include more research models. Hence, the North America region is expected to grow at a faster rate due to rising preclinical activities by pharmaceutical companies, and growing cancer research in this region.

Competitive Landscape

The leading players in the global Patient Derived Xenograft Models Market are Champions Oncology, Inc., Crown Bioscience, Inc., Charles River Laboratories, Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Urolead and Xentech.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Demand for Personalized Medicine
    • 4.2.2 Rising R&D Activities in the Pharmaceutical Industry
    • 4.2.3 Continuous Support for Cancer Research From Public as Well as Private Sector
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Personalized PDX Models
    • 4.3.2 Stringent Regulations Towards Use of Animals Models
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Mice Model
    • 5.1.2 Rats Model
  • 5.2 By Tumor Type
    • 5.2.1 Gastrointestinal Tumor Model
    • 5.2.2 Gynecological Tumor Model
    • 5.2.3 Respiratory Tumor Model
    • 5.2.4 Other Tumor Model
  • 5.3 By End User
    • 5.3.1 Pharmaceutical & Biotechnology Companies
    • 5.3.2 Academic & Research Institutions
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Champions Oncology, Inc.
    • 6.1.2 Charles River Laboratories, Inc.
    • 6.1.3 Crown Bioscience, Inc.
    • 6.1.4 EPO Berlin-Buch GmbH
    • 6.1.5 Hera BioLabs
    • 6.1.6 Horizon Discovery Group plc,
    • 6.1.7 Oncodesign
    • 6.1.8 Pharmatest Services Ltd
    • 6.1.9 Urolead
    • 6.1.10 Xentech

7 MARKET OPPORTUNITIES AND FUTURE TRENDS